PL360280A1 - Use of baculovirus vectors in gene therapy - Google Patents

Use of baculovirus vectors in gene therapy

Info

Publication number
PL360280A1
PL360280A1 PL36028001A PL36028001A PL360280A1 PL 360280 A1 PL360280 A1 PL 360280A1 PL 36028001 A PL36028001 A PL 36028001A PL 36028001 A PL36028001 A PL 36028001A PL 360280 A1 PL360280 A1 PL 360280A1
Authority
PL
Poland
Prior art keywords
gene therapy
baculovirus vectors
baculovirus
vectors
therapy
Prior art date
Application number
PL36028001A
Other languages
Polish (pl)
Inventor
Seppo Yla-Herttuala
Kari J. Airenne
Original Assignee
Ark Therapeutics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ark Therapeutics Limited filed Critical Ark Therapeutics Limited
Publication of PL360280A1 publication Critical patent/PL360280A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/14011Baculoviridae
    • C12N2710/14111Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL36028001A 2000-05-26 2001-05-29 Use of baculovirus vectors in gene therapy PL360280A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0012997.3A GB0012997D0 (en) 2000-05-26 2000-05-26 Gene delivery
PCT/GB2001/002383 WO2001090390A1 (en) 2000-05-26 2001-05-29 Use of baculovirus vectors in gene therapy

Publications (1)

Publication Number Publication Date
PL360280A1 true PL360280A1 (en) 2004-09-06

Family

ID=9892534

Family Applications (1)

Application Number Title Priority Date Filing Date
PL36028001A PL360280A1 (en) 2000-05-26 2001-05-29 Use of baculovirus vectors in gene therapy

Country Status (13)

Country Link
EP (1) EP1283894A1 (en)
JP (1) JP2003533992A (en)
KR (1) KR20030072213A (en)
CN (1) CN1430675A (en)
AU (1) AU2001258657A1 (en)
CA (1) CA2413326A1 (en)
GB (1) GB0012997D0 (en)
HU (1) HUP0302119A3 (en)
IL (1) IL153070A0 (en)
MX (1) MXPA02011517A (en)
NO (1) NO20025657L (en)
PL (1) PL360280A1 (en)
WO (1) WO2001090390A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096469A2 (en) * 2001-05-29 2002-12-05 Ark Therapeutics Ltd. Gene delivery via a baculovirus vector
US8906676B2 (en) 2004-02-02 2014-12-09 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
KR101699142B1 (en) 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 Novel antigen-binding polypeptides and their uses
CN103520735B (en) 2004-12-22 2015-11-25 Ambrx公司 Comprise non-naturally encoded amino acid whose formulations of human growth hormone
JP2008525473A (en) 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド Modified human growth hormone
CA2590429C (en) 2004-12-22 2014-10-07 Ambrx, Inc. Compositions of aminoacyl-trna synthetase and uses thereof
MX2007007591A (en) 2004-12-22 2007-07-25 Ambrx Inc Methods for expression and purification of recombinant human growth hormone.
SG158148A1 (en) 2004-12-22 2010-01-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
JP2008541769A (en) 2005-06-03 2008-11-27 アンブレツクス・インコーポレイテツド Improved human interferon molecules and their use
PT2339014E (en) 2005-11-16 2015-10-13 Ambrx Inc Methods and compositions comprising non-natural amino acids
ES2465473T3 (en) 2006-09-08 2014-06-05 Ambrx, Inc. Transcription of arnt suppressor in vertebrate cells
KR20090060294A (en) 2006-09-08 2009-06-11 암브룩스, 인코포레이티드 Modified human plasma polypeptide or fc scaffolds and their uses
CN104163864B (en) 2007-03-30 2017-08-01 Ambrx公司 Through modifying the polypeptides of FGF 21 and its purposes
AU2008247815B2 (en) 2007-05-02 2012-09-06 Ambrx, Inc. Modified interferon beta polypeptides and their uses
JP5547083B2 (en) 2007-11-20 2014-07-09 アンブルックス,インコーポレイテッド Modified insulin polypeptides and their use
CN103694337B (en) 2008-02-08 2016-03-02 Ambrx公司 Modified leptin polypeptide and its purposes
UA118536C2 (en) 2008-07-23 2019-02-11 Амбркс, Інк. MODIFIED Bovine granulocyte colony-stimulating factor polypeptide and its application
CN101358204B (en) * 2008-08-29 2011-05-18 浙江理工大学 Method for preparing cellular membrane and cellular organelle membrane protein after human enveloped virus budding
KR101647164B1 (en) 2008-09-26 2016-08-09 암브룩스, 인코포레이티드 Modified animal erythropoietin polypeptides and their uses
NZ607477A (en) 2008-09-26 2014-09-26 Ambrx Inc Non-natural amino acid replication-dependent microorganisms and vaccines
CN107056929A (en) 2009-12-21 2017-08-18 Ambrx 公司 Porcine somatotropin polypeptide and its purposes by modification
CN107674121A (en) 2009-12-21 2018-02-09 Ambrx 公司 Bovine somatotropin polypeptide and its purposes by modification
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
MX346786B (en) 2010-08-17 2017-03-31 Ambrx Inc Modified relaxin polypeptides and their uses.
AR083006A1 (en) 2010-09-23 2013-01-23 Lilly Co Eli FORMULATIONS FOR THE STIMULATING FACTOR OF COLONIES OF GRANULOCITS (G-CSF) BOVINE AND VARIANTS OF THE SAME
PL3412302T3 (en) 2014-10-24 2021-11-02 Bristol-Myers Squibb Company Modified fgf-21 polypeptides and uses thereof
CN110637027B (en) 2017-02-08 2024-08-30 百时美施贵宝公司 Modified relaxin polypeptides comprising pharmacokinetic enhancers and uses thereof
CN114736929B (en) * 2022-05-16 2023-06-09 睿征医药科技(武汉)有限公司 Composition, method and application for producing recombinant baculovirus in insect cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE287271T1 (en) * 1996-11-01 2005-02-15 Ark Therapeutics Ltd USE OF VEGF FOR PRODUCING A MEDICATION FOR TREATING OR PREVENTING INTIMAL HYPERPLASIA AND ADMINISTRATION DEVICE
DE19735593C2 (en) * 1997-08-15 1999-08-26 Hepavec Ag Fuer Gentherapie Coat protein-modified baculovirus vector for gene therapy
EP1100946A1 (en) * 1998-07-24 2001-05-23 Aventis Pharma S.A. Vectors derived from baculovirus and use for transferring nucleic acids into nerve cells of vertebrates

Also Published As

Publication number Publication date
JP2003533992A (en) 2003-11-18
NO20025657D0 (en) 2002-11-25
KR20030072213A (en) 2003-09-13
CA2413326A1 (en) 2001-11-29
MXPA02011517A (en) 2004-01-26
EP1283894A1 (en) 2003-02-19
NO20025657L (en) 2002-11-25
CN1430675A (en) 2003-07-16
WO2001090390A9 (en) 2003-01-09
HUP0302119A2 (en) 2003-09-29
IL153070A0 (en) 2003-06-24
WO2001090390A1 (en) 2001-11-29
GB0012997D0 (en) 2000-07-19
HUP0302119A3 (en) 2005-12-28
AU2001258657A1 (en) 2001-12-03

Similar Documents

Publication Publication Date Title
HUP0302119A3 (en) Use of baculovirus vectors in gene therapy
IL152549A0 (en) Vectors for ocular transduction and use thereof for genetic therapy
AU1194802A (en) DNA expression vectors and methods of use
AU2002367262A8 (en) Personal user agent
GB0004003D0 (en) Therapeutic agents
HUP0401903A3 (en) Improved use of et-743 in cancer thereapy
GB0005789D0 (en) Therapeutic agents
GB0003254D0 (en) Heterocyclic compounds and their therapeutic use
AU2002303261A8 (en) Gene brcc2 and diagnostic and therapeutic uses thereof
GB0000564D0 (en) Therapeutic agents
GB0119025D0 (en) Compounds and their therapeutic use
EP1317271A4 (en) Therapeutic and cosmetic uses of heparanases
GB0018887D0 (en) Compound and their therapeutic use
GB0008966D0 (en) Vectors for gene therapy
GB2376943B (en) Compounds and their therapeutic use
GB0112237D0 (en) Compounds and their therapeutic use
TW423322U (en) Improved structure of massage pad
GB0012945D0 (en) Use of compounds in therapy
GB0017625D0 (en) Use of compounds in therapy
GB0030058D0 (en) Use of compounds in therapy
GB0014526D0 (en) Massage/manipulation ball
GB0017028D0 (en) Peptides and their therapeutic use
GB0118627D0 (en) Use of compounds in therapy
GB0023473D0 (en) Therapeutic use and formulation
GB0018886D0 (en) Compounds and their therapeutic use

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)